GAPDH and cardiac hypertrophy: We demonstrated that co‐treatment with SE and harmine significantly decreased key metabolic markers, including LA, PA, G6P, the NAD+/NADH ratio, the activity of GAPDH, and ATP production in AngII‐induced cardiac hypertrophy models (Figure 5B).